Abstract 4027
Background
Recent advances in cancer therapies have resulted in a greater number of people receiving chemotherapy in ambulatory care settings worldwide. In Spain emergency departments, is the single point of entry to acute inpatient services, and therefore play a pivotal role in the immediate management of chemotherapy complications. This study set out to explore ED use by ambulatory patients receiving anti-cancer agents in febrile neutropenia episodes. Data will contribute to service innovation for optimal patient care and health service efficiency.
Methods
A 12 month retrospective observational study of unplanned ED presentation by patients within 30 days of receiving anti-cancer therapy for a range of cancer diagnoses.
Results
The preliminary main results are the following. There were 382 ED presentations of chemotherapy related FN in cancer patients and a sample of 170 were selected in regards to a 30-day frame between the FN episode and the chemotherapy administration. The most common diagnoses were breast (33/170; 19.4%); bowel (32/170; 18.8%) and genitourinary cancers (30/170; 17.6%). A total of 145 (145/170; 85.2%) were given a triage level III and the rest (25/170; 14.7%) a triage level II.
Conclusions
There is still some important data to exploit such as median time from triage to medical attention and median time from triage to antibiotic, which will allow the researchers to establish the percentage of compliance with evidence based guidelines. As reported in international literature the compliance is challenging in a busy and unpredictable ED setting. Therefore it will be interesting to measure our compliance rates and explore opportunities to further improve adherence to evidence-based guidelines and aim for better clinical outcomes in case our results correlate with current literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ethic Committee Hospital Clinic Barcelona.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract